Successful re-challenge of dabrafenib-trametinib combination therapy in advanced BRAF(V600E)-mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report

BACKGROUND: Patients with v-raf murine sarcoma viral oncogene homolog B1 (BRAF)(V600E)-mutant non-small cell lung cancer (NSCLC) benefit from treatment with a combination of BRAF and mitogen-activated protein kinase (MEK) inhibitors, but resistance and disease progression develop in most patients. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Yaran, Ren, Yaqian, Yan, Bing, Li, Zhaona, Huang, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577789/
https://www.ncbi.nlm.nih.gov/pubmed/36267742
http://dx.doi.org/10.21037/atm-22-3887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577789/
https://www.ncbi.nlm.nih.gov/pubmed/36267742
http://dx.doi.org/10.21037/atm-22-3887

Ejemplares similares